Resalis Therapeutics
Resalis Therapeutics develops RNA-based therapies targeting the underlying causes of complex metabolic disorders, specifically obesity and fatty liver diseases like MAFLD/MASH. Its lead drug candidate, RES-010, is a non-coding RNA molecule designed to provide sustained weight loss and improved metabolic health. The company is currently advancing this candidate through Phase 1 clinical trials.
Visit websiteTorino, Italy
Biotechnology
Healthcare
Therapeutics
Funding summary
- Total raised
- €20.0M
- Funding rounds
- 2
Investors in Resalis Therapeutics
Investors on record for Resalis Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Resalis Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors